Published Date: 17 Jul 2024
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two of the most common prostate conditions among elderly men, with a significant percentage experiencing one or both conditions. Prostate cancer is the most ...
Read Full NewsNew UBC Okanagan research shows that exercise can do more than improve the strength and cardiovascular endurance of women who have survived breast cancer.
UCLA scientists, together with a team of international collaborators, have identified a promising new treatment strategy that can detect, kill and reprogram aggressive, treatment-resistant tumors like osteosarcomas and glioblastoma.
A research team led by Cancer Center at Illinois (CCIL) member Hua Wang has published new research detailing a new mRNA cancer vaccine platform. The study introduces an immune cell homing hydrogel-based platform designed ...
1.
The Kansas Cancer Center awarded two Indian American doctors professorships.
2.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
3.
The lack of psychiatrists may be addressed by community workers.
4.
Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation
5.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
1.
Machine Learning in Hematology: Boosting Diagnostic Precision and Speed in Medical Practice
2.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
3.
Exploring the Latest Treatments for Essential Thrombocythemia
4.
Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis
5.
The Role of Alanine Aminotransferase in Liver Health and Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation